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ABSTRACT
Most patients with congenital heart disease (CHD) who underwent successful 
shunts defect repair can be remained asymptomatic for years. It leads to a 
high number of losses to follow-up after patients discharge. After closure, 
pulmonary hypertension (PH) prevalence seems to be high and associated with 
increased morbidity and mortality. We reported a 55 y.o. female diagnosed 
with pulmonary arterial hypertension (PAH) and atrial fibrillation (AF) 
31 years after atrial septal defect (ASD) closure by surgery, who never had 
routine follow-up evaluation because she remained asymptomatic for years. 
Physical examination revealed heart enlargement with irregular rhythm and 
pan systolic murmur in the fourth left sternal border. Electrocardiogram 
showed AF normal ventricular response, right axis deviation and suggestive 
for right ventricular hypertrophy. Laboratory testing found the NT pro-BNP 
level was 2,476 pg/mL. The chest X-ray showed enlargement of the heart and 
was representative of PH. From echocardiography study, transthoracic and 
transoesophageal echocardiography, we found no sign of residual shunt. 
There were right atrial and right ventricular dilatation, severe tricuspid 
regurgitation (TR) and a high probability of PH with TR velocity of 4.46 m/s. 
Right heart catheterization concluded mean pulmonary arterial pressure 46 
mmHg, flow ratio 1.1, and pulmonary artery resistance index 15.5 Woods 
unit.m-2. We highlight this case because of the high incidence of PH long 
after defect closure. The high number of lost to follow-up patients can lead to 
morbidity and mortality.
ABSTRAK
Pasien dengan penyakit jantung bawaan yang telah dilakukan koreksi 
kebanyakan tidak bergejala selama bertahun-tahun. Hal ini menyebabkan 
banyak pasien tidak melakukan pemeriksaan evaluasi setelah tindakan 
koreksi. Prevalensi hipertensi paru (HP) tetap tinggi meskipun setelah koreksi 
dan dapat meningkatkan angka morbiditas dan mortalitas. Kami melaporkan 
seorang pasien perempuan berusia 55 tahun yang didiagnosis hipertensi 
arteri paru dan atrial fribrilasi (AF) 31 tahun setelah dilakukan operasi koreksi 
penutupan pada ASD. Pasien ini tidak pernah kontrol rutin untuk evaluasi 
dikarenakan merasa tidak ada keluhan selama bertahun-tahun. Pemeriksaan 
fisik menunjukkan adanya pembesaran jantung dengan irama ireguler dan 
murmur pansistolik pada sela iga 4 parasternal kiri. Elektrokardiogram 
memperlihatkan gambaran AF dengan respon ventrikel normal, deviasi aksis 
ke kanan dan hipertrofi ventrikel kanan. Pada pemeriksaan laboratorium 
didapatkan kadar NT pro-BNP 2.476 pg/mL. Gambaran rontgen thoraks 
menunjukkan adanya pembesaran jantung dan mengarah ke hipertensi 
pari. Pada pemeriksaan ekhokardiogram, baik secara transtorakal maupun 
esofageal, tidak ditemukan adanya residual shunt. Terdapat dilatasi atrium 
dan ventrikel kanan, regurgitasi trikuspid berat dan kemungkinan HP yang 
tinggi dengan TR velocity 4,46 m/s. Pada pemeriksaan kateterisasi jantung 
kanan didapatkan tekanan rerata arteri pulmonal 46 mmHg, flow ratio 1,1 dan 
pulmonary artery resistance indeks 15,5 Woods unit.m-2 Kami mengangkat 
kasus ini karena tingginya angka kejadian HP setelah tindakan koreksi 
penutupan. Banyaknya pasien yang tidak melakukan pemeriksaan evaluasi 
rutin dapat meningkatkan morbiditas dan mortalitas.
J Med Sci, Volume 53, Number 4, 2021 October:
INTRODUCTION
Congenital heart disease (CHD) with 
left-to-right shunt is one of the causes of 
pulmonary hypertension (PH) group 1 or 
pulmonary artery hypertension (PAH). 
The estimation of PH related to CHD in 
western countries is about 5-10%.1 In 
Indonesia, the prevalence data of CHD 
is still not available. Still, the data from 
the single centre show more than 1012 
new CHD patients within five years of 
the registry, and most of them were 
atrial septal defect (ASD).2 For those with 
uncorrected left-to-right shunt CHD with 
PH have higher morbidity and mortality 
compared to others. If the shunt is left 
unrepaired, the risk of developing PH 
increased. However, the risk of PH after 
defect repair increased because of prior 
pressure and volume overload in the 
pulmonary vasculature.3
The CHD associated with PAH (CHD-
PAH) includes a condition after surgical 
or percutaneous shunt closure. The 
PAH can be developed immediately or 
recurred years after closure without 
signs of residual lesions after the 
procedure. Prognosis of patients who 
develop PAH after closure is worse than 
those with uncorrected CHD-PAH. This 
condition has caused concerns regarding 
repairing the defect in CHD patients with 
PAH.4 Here, we presented a case with PH, 
which developed several years after ASD 
closure by surgery.
CASE
A 55 y.o. female came to the PH 
clinic with shortness of breath with 
activity five years ago. The symptoms 
worsened in recent months and were 
followed by swollen legs. Because of her 
deteriorating condition, she consulted 
with a cardiologist and was referred to 
our hospital. She had been diagnosed 
with ASD and had performed defect 
closure by surgery when she was 24 y.o. 
Since there were no symptoms appeared 
after the surgery, she decided not to have 
regular follow-up evaluation.
The patient looked dyspneic during 
the current examination, with blood 
pressure 135/87 mmHg, heart rate 85 
times/min, respiratory rate 20 times/
min, and peripheral oxygen saturation 
97%. Physical examination revealed an 
enlargement of the heart with irregular 
rhythm and pan systolic murmur best 
heard in the fourth left sternal border.
The electrocardiogram (FIGURE 1) 
showed atrial fibrillation with a normal 
ventricular response, right axis deviation, 
right ventricular hypertrophy and non-
frequent ventricular extrasystole. The 
laboratory investigation demonstrated a 
haemoglobin level of 13.6 g/dL, and white 
blood cells count 11.48 × 103/µL, platelet 
count of  237× 103/µL, creatinine level 1.14 
mg/dL, blood glucose 116 mg/dL and NT 
pro-BNP level of 2,476 pg/mL. The chest 
X-ray (FIGURE 2) showed enlargement of 
the heart with cardiothoracic ratio ( CTR 
) > 0.65 and suggestive for PH.
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FIGURE 1. Electrocardiography of patient
FIGURE 2. Chest X-ray of patient
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The transthoracic echocardiography 
(FIGURE 3) showed right atrial and right 
ventricular dilatation, left ventricle 
D-shaped, left ventricular ejection 
fraction (LVEF) 70%, no residual ASD, 
severe tricuspid regurgitation (TR) 
and high probability of PH with TR 
velocity 4.46 m/s. The transoesophageal 
echocardiography revealed interatrial 
septum (IAS) and interventricular 
septum (IVS) were intact and no residual 
shunt with severe TR. In the 6-min walk 
test, she walked 160 m.
The patient proceeded to get right 
heart catheterization (RHC). The result 
of RHC indicated increased mean 
pulmonary artery pressure (mPAP) as 
high as 46 mmHg, flow ratio (FR) 1.1 and 
pulmonary artery resistance index (PARI) 
of 15.5 Woods unit.m-2. The patient was 
diagnosed with PAH after ASD closure 
and currently atrial fibrillation normal 
ventricular response. She was treated 
with oral sildenafil 20 mg t.i.d, oral 
digoxin 0.25 mg q.i.d and warfarin 2 mg 
q.i.d at night. After treatment, she showed 
an improvement in functional class. She 
also demonstrated an increased distance 
in the 6-min walk test (435 m). The level 
of NT pro-BNP decreased to 1,070 pg/mL. 
There is also no sign of the adverse effect 
of sildenafil. The result from regular 
follow-up is shown in TABLE 1.
FIGURE 3. TTE
TABLE 1. Follow-up result
Time NT pro-BNP (pg/mL) 6MWD (m) SaO2 (%)
Mar 2018 2,467 160 97
Feb 2019 2,034 345 98
Sep 2019 1,545 422 96
Mar 2020 1,070 435 97
DISCUSSION
Pulmonary hypertension is explained 
as an mPAP >20 mmHg. In comparison, 
PAH is a pulmonary vascular disease 
that is described by mPAP >20 mmHg, 
pulmonary capillary wedge pressure 
(PCWP) <15 mmHg and pulmonary 
vascular resistance (PVR) > 3 Woods unit 
as assessed by RHC.5,6 A PH related with 
congenital heart disease with a left to 
right shunt is admitted in group 1 of the 
classification of PH or PAH.7 A CHD-PAH 
on the patients with ASD with significant 
left to right shunt, with Qp/Qs >1.5, signs 
of right ventricular overload, PVR <5 
Woods unit and PVR/SVR <0.3 should be 
closed regardless of the symptom.8 This 
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defect can be repaired either by surgery 
or device depend on the type of ASD and 
eligibility for closure.9
Our patient was diagnosed with ASD 
secundum and had closure by surgery 
when she was 24 y.o. Unfortunately, 
we do not have data before surgery 
from her earlier hospital. After 
surgery, she never had routine follow-
up examinations. Since last year she 
became easily tired and had shortness 
of breath. The 2015 European Society of 
Cardiology Guidelines about Diagnosis 
and Management of PH recommend that 
the CHD-PAH be grouped into 4, namely 
Eisenmenger's syndrome, PAH related 
with prevalent systemic-to-pulmonary 
shunts, and PAH with small/coincidental 
defects and PAH after defect correction.10 
This patient could be classified in the last 
group, where the PAH persisted instantly 
after closure or developed months or 
years later. She had had ASD closure by 
surgery in adolescence and remained 
asymptomatic decades later. D'alto et 
al.4 stated PH might develop or become 
symptomatic years after shunt closure 
in people with PVR >5 Woods unit, PVRI 
>6 Woods unit.m-2, and PVR/SVR >0.33. 
Unfortunately, we did not have the 
patient's data before operated because 
this patent was surgeried in another 
hospital 31 y.o.4
German National CHD Registry 
reported PH prevalence of 3.0% among 
825 simple lesions such as ASD, VSD and 
PDA patients that have already been 
corrected. In that study, symptomatic PH 
developed after a median follows up of 
15.9 years after shunt repair. The mean 
age at the time of closure was higher in the 
PH group compared to the no PH group. 
Patients with PH had a higher morbidity 
and mortality risk. In confirming the 
diagnosis of PH, it is recommended to 
life-long monitoring and low threshold 
for examination, which has a significant 
clinical and prognostic purpose. This 
study also showed that the prevalence of 
PH was increased mainly after 50 years 
of life. The highest PH risk was found in 
the group of PDA patients, followed by 
ASD and VSD.3
In a systematic review and meta-
analysis evaluating PH prevalence 
after ASD closure percutaneously, they 
reported a decrease in the prevalence 
of PH from 44 to 18% after closure 
procedures at a mean follow-up of 15-60 
months. They also reported a significant 
variation in the PH prevalence among 
the literatures reviewed, with the highest 
prevalence being found in studies with 
small samples. This systematic review 
involving 15 studies showed that there is 
still a decline in PH prevalence until 60 
months of follow-up after ASD closure.11
Another systematic review and 
meta-analysis studying PAH prevalence 
in ASD before and after ASD closure 
(surgical or percutaneous) at adult age 
reported that prevalence of PAH before 
ASD closure ranged from 29-70% and 
5-50% after closure within a mean 
follow-up range of 13-98 months. After 
closure, the PAH prevalence in ASD is 
considered highest in studies with older 
dates, small study cohorts with small 
sample sizes, and studies with high 
follow-up loss. A sensitivity analysis was 
conducted excluding all high numbers 
of a follow-up loss study, which resulted 
in the prevalence of PAH  42 and 16% 
in ASD before and closure, respectively. 
This study also mentioned a significant 
reduction of mean PAP, which is 34±10 
before closure and 28±10 after closure.12
The follow-up of patients with post 
ASD closure should evaluate a residual 
shunt, right ventricle dimension and 
function, TR and estimated PAP by 
echocardiography. The diagnosis of 
arrhythmia by electrocardiography 
and Holter evaluation is essential. 
Those with residual shunt increased 
mPAP or arrhythmias. Those repaired 
at adults age should undergo routine 
follow up assessment for the first two 
years depending on the result; every 
3-5 years is reasonable.9 Another 
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guideline stated that physiological and 
haemodynamically stable patients could 
be assessed for routine follow up every 
2-5 years. But for moderate and severely 
ill patients should have more frequent 
follow-up evaluations (including history, 
electrocardiography, echocardiography, 
pulse oximetry and exercise test) about 
every 3-12 months depends on the 
result.13
Until now, there are no specific 
guidelines that recommend how long the 
total duration of follow-up evaluation 
should be conducted in ASD patients after 
closure. Even so, there is a report from 
the Dutch Congenital Corvitia registry 
mentioned that from 1.103 patients with 
the shunt (474 of them are ASD), there is a 
total incidence of PH shortly after repair 
for 2.1% (95% CI:0.3-0.77) and >15% (95% 
CI:2.6-23.8) 50 years after repair. This 
report explains the progress of PH after 
shunt closure.14 The progression of PH 
is possible because of the excess volume 
and pressure resulting in damage to the 
pulmonary vessels, which in time lead to 
PH.15 There are some studies mentioning 
risk factors of PH development after 
ASD closure. Patients with ASD closure 
at older age (especially >40 y.o.) are 
more likely become PH. As well as 
those with residual shunt, elevated 
PAP or arrhytmias should be evaluated 
regularly.9
CONCLUSION
We reported a 55 y.o. female 
diagnosed with PAH and atrial fibrillation 
31 years after ASD closure by surgery. 
This condition is possible because PAH 
can be found and developed over time 
after closure. PAH can occur immediately 
or years after surgery. Therefore, routine 
and careful follow-up evaluation after 
defect closure is needed.
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